Disease or Syndrome
Amylyx Acquires GLP-1 Receptor Antagonist for $35M to Fill Pipeline Gap
Amylyx Pharmaceuticals, Relyvrio, GLP-1 receptor antagonist, Eiger Biopharma, pipeline expansion, ALS, Wolfram syndrome
Fractyl Highlights GLP-1 Gene Therapy Potential, Delays Clinical Trials to 2025
Fractyl, GLP-1 gene therapy, clinical trials, diabetes, ADA24
Vertex Announces Positive Results for VX-880 in Type 1 Diabetes Treatment
Vertex Pharmaceuticals, VX-880, Type 1 Diabetes, Stem Cell Therapy, Insulin Independence, Severe Hypoglycemic Events
Jazz Pharmaceuticals’ Essential Tremor Drug Candidate Fails to Meet Primary Endpoint in Phase IIb Trial
Jazz Pharmaceuticals, suvecaltamide, essential tremor, phase IIb trial, primary endpoint, calcium channel modulator
FDA Expands Approval of Sarepta’s Gene Therapy for Duchenne Muscular Dystrophy to Include Older Boys and Non-Ambulatory Patients
FDA, Sarepta, Duchenne Muscular Dystrophy, Gene Therapy, Elevidys, Ambulatory, Non-Ambulatory, Expanded Approval
Johnson & Johnson to Appeal $150 Million Verdict in HIV Meds Off-Label Marketing Case
Johnson & Johnson, HIV Meds, Off-Label Marketing, Appeal, $150 Million Verdict
Kyverna’s CAR-T Relapse in Lupus Dents Autoimmune Hopes Amid Biotech Gold Rush
Kyverna, CAR-T, Lupus, Autoimmune Disease, Biotech, Gold Rush, Relapse, Clinical Trials, Gene Therapy
Silence’s siRNA therapy maintains Lp(a) lowering in cardiovascular study
Lp(a ), RNA, Small Interfering, Cardiovascular Diseases
AbbVie’s Skyrizi Secures Key FDA Approval for Ulcerative Colitis Treatment
Skyrizi, AbbVie, FDA approval, ulcerative colitis, inflammatory bowel disease, IL-23 inhibitor, Crohn’s disease
FDA Approves Keytruda for Primary Advanced or Recurrent Endometrial Carcinoma and Skyrizi for Ulcerative Colitis
Keytruda, pembrolizumab, endometrial carcinoma, Skyrizi, risankizumab-rzaa, ulcerative colitis, FDA approval